Analysts’ downgrades for Thursday, October 12th:

American Express (NYSE:AXP) was downgraded by analysts at Compass Point from a buy rating to a neutral rating. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

BorgWarner (NYSE:BWA) was downgraded by analysts at Deutsche Bank AG from a buy rating to a hold rating. The firm currently has $55.00 price target on the stock.

Delphi Automotive PLC (NYSE:DLPH) was downgraded by analysts at Deutsche Bank AG from a buy rating to a hold rating. Deutsche Bank AG currently has $107.00 target price on the stock.

NanoString Technologies (NASDAQ:NSTG) was downgraded by analysts at Janney Montgomery Scott from a buy rating to a neutral rating.

Shaw Communications (NYSE:SJR) (TSE:SJR.B) was downgraded by analysts at Scotiabank from an outperform rating to a sector perform rating.

Ulta Beauty (NASDAQ:ULTA) was downgraded by analysts at Cleveland Research from a buy rating to a neutral rating.

Visteon Corporation (NYSE:VC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Visteon Corp. operates as an automotive supplier engaged in the design, engineering and manufacturing of innovative climate, electronic, interior and lighting products for vehicle manufacturers. Products offered by the Company includes climate systems, powertrain control systems, engine induction systems, cockpit modules, front and rear lighting systems, engine management systems, and electronic products comprising integrated solutions, audio and infotainment, analog/digital instrument cluster, displays, control panel. Markets served by the Company include original equipment manufacturers and automotive aftermarket. Visteon Corp. is headquartered in Michigan, USA. “

Veracyte (NASDAQ:VCYT) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. “

Vermilion Energy (NYSE:VET) (TSE:VET) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Vermilion Energy Inc. is an international oil and gas producer with properties in Western Canada, Australia, France and the Netherlands. Vermilion Energy Inc, formerly known as Vermilion Energy Trust, is based in Calgary, Canada. “

Voestalpine Ag (NASDAQ:VLPNY) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “voestalpine AG is engaged in the production, processing and distribution of steel products. Its operating division consists of Steel, Special Steel, Metal Engineering, Metal Forming and Other. Steel division focuses on the production and processing of flat steel products for the automotive, white goods and construction industries. Special Steel division segment manufactures tool steel and high-speed steel. Metal Engineering division produces rails and turnout products, rod wire, drawn wire, premium seamless tubes and welding filler materials. Metal Forming division offers special sections, tube products, and precision strip steel as well as pre-finished system components. Other segment provides coordination services and assistance to the subsidiaries. voestalpine AG is headquartered in Linz, Austria. “

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “

Vantiv (NYSE:VNTV) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Vantiv, Inc. is an integrated payment processor engaged in providing advanced technology solutions for businesses and financial institutions. The Company operates in two segments: Merchant Services and Financial Institution Services. Vantiv offers acquiring and processing transactions, value-added services, merchant services and reporting for electronic payment transactions. It also provides card issuer processing, payment network processing, fraud protection, card production, prepaid program management, automated teller machine driving, network gateway and switching services. Vantiv, Inc. is headquartered in Cincinnati, Ohio. “

Validus Holdings (NYSE:VR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Validus Holdings, Ltd., through its principal operating subsidiary Validus Reinsurance, Ltd., is a global provider of short-tail lines of reinsurance including property catastrophe, property pro-rata and property per risk, marine and energy, and other specialty lines. Validus was formed in December following the significant natural catastrophes of 2005 with an experienced management team and an unencumbered capital base of approximately $one billion. “

Virtus Investment Partners (NASDAQ:VRTS) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Virtus Investment Partners, Inc., headquartered in Hartford, Connecticut, provides investment management products and services to individuals and institutions in the United States. . It operates a multi-manager asset management business, comprising a number of individual affiliated managers, each with a distinct investment style, autonomous investment process and individual brand. Investors have an array of needs and Virtus Investment Partners offers a variety of investment styles and multiple disciplines to meet those needs. The Company provides its products in a number of forms and through multiple distribution channels. Its retail products include open-end mutual funds, closed-end funds and separately managed accounts. The Company manages institutional accounts for corporations, multi-employer retirement funds and foundations, endowments, special purpose funds and other types of institutions. “

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable. The company reduced its debt by $4.8 billion and expects to meet its target of $5 billion debt reduction ahead of schedule. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Valeant trimmed its guidance due to recent divestitures. However, weakness in the dermatology business persists. Shares have underperformed the industry.”

Vivint Solar (NYSE:VSLR) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Vivint Solar Inc. is a provider of residential solar energy systems in the United States. It designs, installs, and maintains cost-effective solar energy systems. The Company also offers photovoltaic installation software products and devices. Vivint Solar, Inc. is headquartered in Provo, Utah. “

AquaVenture Holdings (NASDAQ:WAAS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “AquaVenture Holdings LLC is a provider of Water-as-a-Service (TM) solutions. It offers clean drinking and process water. The Company’s operating platform consists of Quench, a U.S.-based provider of Point-of-Use, filtered water systems and related services to institutional and commercial customers and Seven Seas Water, a provider of desalination and wastewater treatment solutions to governmental, municipal, industrial and hospitality customers. AquaVenture Holdings LLC is based in TAMPA, United States. “

Wesco Aircraft Holdings (NYSE:WAIR) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Wesco Aircraft Holdings, Inc. distributes and provides supply chain management services to the global aerospace industry. It offers inventory of aerospace parts, including hardware, bearings, tools, electronic components and machined parts. The Company’s services range from traditional distribution to the management of supplier relationships, quality assurance, kitting, just-in-time delivery and point-of-use inventory management. Wesco Aircraft Holdings, Inc. is headquartered in Valencia, California. “

Receive News & Ratings for American Express Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Express Company and related companies with MarketBeat.com's FREE daily email newsletter.